The introduction of biologic therapies for hidradenitis suppurativa (HS) has “revolutionized” treatment for the rare inflammatory skin condition, though there’s still plenty of progress to be made, ...
As with other medications, Humira can interact with certain other drugs. It can also interact with some vaccines. An interaction occurs when one substance causes another substance to have a different ...
SPRINGFIELD, Mass. (WWLP) – Health New England announced Monday that it will shift coverage of the biologic drug Humira to more affordable FDA-approved biosimilars starting next month for members of ...
In May 2025, the FDA approved numerous biosimilars as interchangeable with Stelara ® (ustekinumab) and Humira ® (adalimumab), bringing the total number of Stelara ® interchangeables to four, plus an ...
Zacks.com on MSN
How Strong Is AbbVie's Immunology Franchise After Humira's LOE?
AbbVie ABBV is a dominant player in the immunology space, powered by three blockbuster drugs — Skyrizi, Rinvoq and Humira — ...
Medicare Part D may cover Humira when a person can self-administer it at home. A person’s Part D costs for Humira will depend on the plan’s formulary and their specific plan. Similarly, Medicare ...
(Reuters) - UnitedHealth Group said on Tuesday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of Jan. 1, 2025, and ...
UnitedHealth Group Inc. (NYSE:UNH) reportedly announced on Tuesday that it will remove AbbVie Inc.’s (NYSE:ABBV) blockbuster drug Humira from some of its preferred reimbursement lists starting January ...
Blue Shield of California will purchase Idacio at $525 per dose, significantly cheaper than Humira's $2100 price, enhancing affordability for patients. Collaboration with Fresenius Kabi and Evio ...
Please provide your email address to receive an email when new articles are posted on . Celltrion’s Yuflyma is a high concentration, citrate-free formulation of adalimumab. It is the ninth Humira ...
Hosted on MSN
AbbVie retains Humira market share above 70%: report
AbbVie (NYSE:ABBV) has managed to keep its market share for its bestselling arthritis therapy, Humira, above 70%, generic drugmaker Samsung Bioepis said in a new report on Thursday as the blockbuster ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback